For part 3 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the favorable safety ...

ELLSWORTH, Kan. (KSNW) – A woman from Ellsworth is navigating life with a rare neuromuscular disease. Tina Bruning learned of her diagnosis of generalized myasthenia gravis, or gMG, in May 2021. A ...

BofA analyst Jason Gerberry lowered the firm’s price target on Immunovant (IMVT) to $38 from $45 and keeps a Buy rating on the shares. The firm ...

H.C. Wainwright reaffirmed their Buy rating on Immunovant (NASDAQ:IMVT) shares with a price target of $51.00, aligning with the broader Wall Street sentiment. According to InvestingPro data, analyst ...

Guggenheim Securities adjusted its price target for Immunovant shares, listed on (NASDAQ:IMVT), to $44.00, a decrease from the previous $46.00, while sustaining a Buy rating on the stock. Currently ...

The FDA has approved Alexion's Soliris for use in patients with treatment resistant generalised Myasthenia gravis (gMG), making it the first new therapy for the condition in 60 years. The approval ...

SE (NASDAQ:ARGX – Get Free Report) has earned an average rating of “Moderate Buy” from the twenty-two ratings firms that are presently covering the firm, Marketbeat.com reports. One investment analyst ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

New research at the University of Alberta may make it easier to diagnose serious diseases that disrupt the body's energy ...

The Janus Henderson Global Life Sciences Fund returned -11.16% and the MSCI World Health Care IndexSM returned -11.40%. Click ...